An ongoing immune response can be represented by the upregulation of immune checkpoints (CTLA4, PD-1/PD-L1, IDO and members of the CD33-like siglecs i.e., siglec-7 and siglec-9, but their expression on tumor cells can also be driven by oncogenic pathways. Here, CTLA4 is linked to neoplasm.